应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
06821 凯莱英
未开盘 10-16 16:08:16
137.600
-3.600
-2.55%
最高
150.000
最低
130.200
成交量
108.32万
今开
143.300
昨收
141.200
日振幅
14.02%
总市值
498.11亿
流通市值
38.30亿
总股本
3.62亿
成交额
1.50亿
换手率
3.89%
流通股本
2,783万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
凯莱英（002821）10月16日主力资金净卖出1.54亿元
证券之星 · 10-19 09:12
凯莱英（002821）10月16日主力资金净卖出1.54亿元
异动解读｜凯莱英盘中下跌5.03%，机构减持压力与避险情绪持续压制
行情直击 · 10-16
异动解读｜凯莱英盘中下跌5.03%，机构减持压力与避险情绪持续压制
异动解读｜凯莱英盘中上涨3.46%，公募加仓与业绩窗口临近提振情绪
行情直击 · 10-15
异动解读｜凯莱英盘中上涨3.46%，公募加仓与业绩窗口临近提振情绪
凯莱英（002821）10月14日主力资金净卖出1.51亿元
证券之星 · 10-15
凯莱英（002821）10月14日主力资金净卖出1.51亿元
公募首份三季报亮相：不“All in”，权益仓位降到59％，凯莱英升至第一大重仓股
华夏时报网 · 10-15
公募首份三季报亮相：不“All in”，权益仓位降到59％，凯莱英升至第一大重仓股
异动解读｜凯莱英盘中下跌3.19%，机构减持压力与避险情绪持续压制
行情直击 · 10-14
异动解读｜凯莱英盘中下跌3.19%，机构减持压力与避险情绪持续压制
公募首份三季报出炉，南方港股医药大幅加仓凯莱英、药明康德、恒瑞医药
每日经济新闻 · 10-13
公募首份三季报出炉，南方港股医药大幅加仓凯莱英、药明康德、恒瑞医药
凯莱英的“单点突破”还能走多远？
蓝鲸财经 · 10-13
凯莱英的“单点突破”还能走多远？
异动解读｜凯莱英盘中下跌3.07%，机构密集减持叠加节后避险情绪压制
行情直击 · 10-13
异动解读｜凯莱英盘中下跌3.07%，机构密集减持叠加节后避险情绪压制
凯莱英（002821）披露董事会会议日期公告，10月09日股价下跌1.52%
证券之星 · 10-09
凯莱英（002821）披露董事会会议日期公告，10月09日股价下跌1.52%
凯莱英（06821）拟于10月22日审议2026年前三季度业绩
公告速递 · 10-09
凯莱英（06821）拟于10月22日审议2026年前三季度业绩
【港股CXO深度剖析】凯莱英的“单点突破”还能走多远？
港股解码 · 10-09
【港股CXO深度剖析】凯莱英的“单点突破”还能走多远？
异动解读｜凯莱英盘中下跌3.37%，机构密集减持叠加节后避险情绪
行情直击 · 10-09
异动解读｜凯莱英盘中下跌3.37%，机构密集减持叠加节后避险情绪
【券商聚焦】中泰国际：多家药企将公布重要数据 推荐创新药与CXO龙头
金吾财讯 · 10-09
【券商聚焦】中泰国际：多家药企将公布重要数据 推荐创新药与CXO龙头
凯莱英（002821）披露证券变动月报表，10月8日股价下跌4.21%
证券之星 · 10-08
凯莱英（002821）披露证券变动月报表，10月8日股价下跌4.21%
异动解读｜凯莱英盘中下跌3.02%，机构减持与节前避险情绪压制股价
行情直击 · 10-08
异动解读｜凯莱英盘中下跌3.02%，机构减持与节前避险情绪压制股价
凯莱英9月股份变动月报：A股注册股本增至334,114,160股
公告速递 · 10-07
凯莱英9月股份变动月报：A股注册股本增至334,114,160股
异动解读｜凯莱英盘中下跌3.87%，机构减持与节前避险情绪压制股价
行情直击 · 10-07
异动解读｜凯莱英盘中下跌3.87%，机构减持与节前避险情绪压制股价
异动解读｜凯莱英盘中下跌3.35%，报160.2港元
行情直击 · 10-02
异动解读｜凯莱英盘中下跌3.35%，报160.2港元
9月30日凯莱英涨5.30%，中欧医疗健康混合A基金重仓该股
证券之星 · 09-30
9月30日凯莱英涨5.30%，中欧医疗健康混合A基金重仓该股
加载更多
公司概况
公司名称：
凯莱英
所属市场：
SEHK
上市日期：
--
主营业务：
凯莱英医药集团（天津）股份有限公司是一家主要从事提供医药外包一站式综合服务的中国公司。该公司的业务包括小分子药物定制研发生产（CDMO）、化学大分子CDMO、临床研究服务、制剂CDMO、生物大分子CDMO、技术输出和合成生物技术。该公司的产品类别涵盖多肽、寡核苷酸、单克隆抗体、抗体偶联药物和信使RNA等。该公司主要在国内外市场开展其业务。
发行价格：
--
{"stockData":{"symbol":"06821","market":"HK","secType":"STK","nameCN":"凯莱英","latestPrice":137.6,"timestamp":1792138096008,"preClose":141.2,"halted":0,"volume":1083230,"delay":0,"changeRate":-0.02549575070821526,"floatShares":27834500,"shares":362000000,"eps":3.711066184261127,"marketStatus":"未开盘","change":-3.6,"latestTime":"10-16 16:08:16","open":143.3,"high":150,"low":130.2,"amount":150291073,"amplitude":0.140227,"askPrice":137.6,"askSize":800,"bidPrice":137.4,"bidSize":2100,"shortable":3,"etf":0,"ttmEps":3.4344167697167567,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":0,"adr":0,"listingDate":1639065600000,"exchange":"SEHK","adjPreClose":141.2,"dividendRate":0.011092,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":1.7072430364094409,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"002821","market":"SZ","secType":"STK","nameCN":"凯莱英","latestPrice":153.58,"timestamp":1792393200000,"preClose":149.1,"halted":0,"volume":9986600,"delay":0,"premium":"-23.71"}},"requestUrl":"/m/hq/s/06821","defaultTab":"news","newsList":[{"id":"2676045579","title":"凯莱英（002821）10月16日主力资金净卖出1.54亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676045579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676045579?lang=zh_cn&edition=full","pubTime":"2026-10-19 09:12","pubTimestamp":1792372325,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月16日收盘，凯莱英报收于149.1元，下跌6.17%，换手率3.42%，成交量10.84万手，成交额16.83亿元。近5日资金流向一览见下表：凯莱英融资融券信息显示，融资方面，当日融资买入9835.68万元，融资偿还1.18亿元，融资净偿还1921.53万元。凯莱英主营业务：全球制药工艺的技术创新和商业化应用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900002441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06821","BK0132","BK0239","BK1191","002821","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133315391","title":"异动解读｜凯莱英盘中下跌5.03%，机构减持压力与避险情绪持续压制","url":"https://stock-news.laohu8.com/highlight/detail?id=1133315391","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133315391?lang=zh_cn&edition=full","pubTime":"2026-10-16 14:34","pubTimestamp":1792132490,"startTime":"0","endTime":"0","summary":"10月16日，凯莱英盘中下跌5.03%，报134.1港元，成交额9133.18万港元。消息面上，近期机构减持与高管减持带来的情绪扰动仍在发酵，市场避险情绪持续压制股价表现。此前公开披露显示，Schroders PLC、摩根大通及南方基金先后减持凯莱英H股，公司执行董事洪亮亦曾减持5.96万股。尽管公司在手订单达16.73亿美元、同比增长53.77%，且将于10月22日披露下一次财报，但短线资金更关注减持信号与情绪面冲击。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"凯莱英盘中走低，机构减持情绪发酵","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132451546","title":"异动解读｜凯莱英盘中上涨3.46%，公募加仓与业绩窗口临近提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1132451546","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132451546?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:45","pubTimestamp":1792028732,"startTime":"0","endTime":"0","summary":"10月15日，凯莱英盘中上涨3.46%，报148.6港元，成交额1690.87万港元。消息面上，公募首份三季报显示，南方港股医药行业混合将凯莱英升至第一大重仓股，并在季内明显加仓创新药及CXO板块，带动市场对公司配置价值的关注回升。同时，公司董事会将于10月22日审议前三季度业绩。此前公司披露在手订单16.73亿美元，同比增长53.77%，叠加化学大分子基地通过美国FDA批准前检查，基本面预期对股价形成支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"凯莱英异动拉升，公募加仓与业绩窗口临近","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675379303","title":"凯莱英（002821）10月14日主力资金净卖出1.51亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675379303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675379303?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:15","pubTimestamp":1792026942,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月14日收盘，凯莱英报收于163.1元，下跌4.98%，换手率1.93%，成交量6.13万手，成交额10.18亿元。近5日资金流向一览见下表：凯莱英融资融券信息显示，融资方面，当日融资买入5470.52万元，融资偿还7601.04万元，融资净偿还2130.52万元。凯莱英主营业务：全球制药工艺的技术创新和商业化应用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500008243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0239","06821","LU1328615791.USD","002821","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675375881","title":"公募首份三季报亮相：不“All in”，权益仓位降到59％，凯莱英升至第一大重仓股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675375881","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675375881?lang=zh_cn&edition=full","pubTime":"2026-10-15 07:55","pubTimestamp":1792022134,"startTime":"0","endTime":"0","summary":"10月13日，南方港股医药行业混合发布2026年第三季度报告，成为公募基金行业首份三季报。报告显示，该基金A、C份额季内净值增长率分别达到18.49%、17.73%，并对创新药及CXO板块的持仓结构进行了明显调整。这份季报的亮相，与三季度医药板块的整体走强形成呼应。医药主题基金从上半年的“陪跑”角色迅速切换为“领跑者”，近三个月主动权益基金涨幅前15名全部被医药主题基金占据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610153896095968.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610153896095968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06821","BK0132","BK0239","BK1191","002821","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199186951","title":"异动解读｜凯莱英盘中下跌3.19%，机构减持压力与避险情绪持续压制","url":"https://stock-news.laohu8.com/highlight/detail?id=1199186951","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199186951?lang=zh_cn&edition=full","pubTime":"2026-10-14 10:43","pubTimestamp":1791945820,"startTime":"0","endTime":"0","summary":"10月14日，凯莱英盘中下跌3.19%，报148.8港元，成交额972.02万港元。消息面上，近期多家机构连续减持凯莱英H股，叠加执行董事洪亮此前减持，市场避险情绪仍对股价形成压制。公开信息显示，Schroders PLC、摩根大通及南方基金先后减持凯莱英H股；公司执行董事洪亮亦于9月15日减持5.96万股。尽管公司在手订单达16.73亿美元、同比增长53.77%，且下一次财报将于10月22日披露，但短线资金更关注减持带来的情绪扰动。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"凯莱英盘中走低，机构减持压制情绪","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675338091","title":"公募首份三季报出炉，南方港股医药大幅加仓凯莱英、药明康德、恒瑞医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2675338091","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675338091?lang=zh_cn&edition=full","pubTime":"2026-10-13 12:19","pubTimestamp":1791865173,"startTime":"0","endTime":"0","summary":"10月13日，证监会官网披露显示，南方港股医药行业混合发布2026年第三季度报告，这也是公募基金行业首份三季报。从该基金发布的季报来看，A、C份额季内净值增长率分别达到18.49%、17.73%，季内大幅加仓了凯莱英、药明康德、恒瑞医药等个股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610133893966047.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610133893966047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0572944931.SGD","LU2580892862.HKD","BK0196","02359","LU1781817850.SGD","LU2125910500.SGD","LU0052750758.USD","LU0359202008.SGD","LU1997245177.USD","603259","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU1064131003.USD","LU0348766576.USD","BK0183","LU2543165471.USD","600276","LU1934453819.USD","01276","LU1255011170.USD","LU1979443071.USD","LU0348767384.USD","LU2097828474.EUR","LU2097828631.EUR","LU1969619763.USD","BK1191","LU2580892789.USD","KURE","LU2242644610.SGD","BK1576","LU1328615791.USD","LU1580142542.USD","BK1141","002821","159718","LU1046422090.SGD","LU1146622755.USD","LU0405327494.USD","LU1808992512.USD","BK0012","LU1820825898.SGD","IE00B543WZ88.USD","LU2289578879.USD","LU1997245094.SGD","06821","LU0456842615.SGD","LU1251922891.USD","LU1655091616.SGD","BK0028","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675838434","title":"凯莱英的“单点突破”还能走多远？","url":"https://stock-news.laohu8.com/highlight/detail?id=2675838434","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675838434?lang=zh_cn&edition=full","pubTime":"2026-10-13 10:19","pubTimestamp":1791857969,"startTime":"0","endTime":"0","summary":"但凯莱英的成长轨迹，或比药明系标的更受全球创新药资本周期牵制。凯莱英的订单对Biotech融资环境敏感度要高于平台型CXO，一旦海外融资再度收紧，新增订单会快速承压；2）小分子赛道产能过剩。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1791512179486029213","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1191","LU1328615791.USD","BK0132","BK0239","002821","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163167335","title":"异动解读｜凯莱英盘中下跌3.07%，机构密集减持叠加节后避险情绪压制","url":"https://stock-news.laohu8.com/highlight/detail?id=1163167335","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163167335?lang=zh_cn&edition=full","pubTime":"2026-10-13 09:41","pubTimestamp":1791855692,"startTime":"0","endTime":"0","summary":"10月13日，凯莱英盘中下跌3.07%，报151.3港元，成交额327.09万港元。消息面上，近期多家机构连续减持凯莱英H股，对市场情绪形成压制。公司执行董事洪亮亦于9月15日减持5.96万股。机构密集调仓叠加节后避险情绪，导致股价承压。公司基本面仍有亮点，在手订单16.73亿美元，同比增长53.77%，化学大分子基地通过美国FDA批准前检查，但短期外资减持压力占据主导。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674724857","title":"凯莱英（002821）披露董事会会议日期公告，10月09日股价下跌1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674724857","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674724857?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:05","pubTimestamp":1791554736,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，凯莱英报收于177.93元，较前一交易日下跌1.52%，最新总市值为644.02亿元。该股当日开盘179.0元，最高181.18元，最低170.1元，成交额达14.58亿元，换手率为2.62%。近日，凯莱英医药集团（天津）股份有限公司发布H股公告，宣布将于2026年10月22日举行董事会会议，主要议程包括考虑及批准公司及其附属公司截至2026年9月30日止九个月的第三季度业绩及其发布，以及其他相关事项。该公告由董事长兼执行董事Hao Hong博士代表董事会出具。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900037871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","06821","BK0239","LU1328615791.USD","002821","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108084006","title":"凯莱英（06821）拟于10月22日审议2026年前三季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1108084006","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108084006?lang=zh_cn&edition=full","pubTime":"2026-10-09 16:37","pubTimestamp":1791535032,"startTime":"0","endTime":"0","summary":"凯莱英医药集团（天津）股份有限公司（06821）10月9日公告称，其董事会将于2026年10月22日（星期四）召开会议，主要议程包括审议并批准公司及其附属公司截至2026年9月30日止九个月的第三季度业绩及相关公告，并处理其他事项（如有）。\\n\\n公告显示，董事会由董事长兼执行董事Hao Hong博士，执行董事杨蕊女士、张达先生及洪亮先生，非执行董事Ye Song博士及张婷女士，以及独立非执行董事孙雪娇博士、侯欣一博士和谢维愷先生组成。\\n\\n凯莱英表示，董事会将于会后及时发布相关业绩信息，供投资者参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674852890","title":"【港股CXO深度剖析】凯莱英的“单点突破”还能走多远？","url":"https://stock-news.laohu8.com/highlight/detail?id=2674852890","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674852890?lang=zh_cn&edition=full","pubTime":"2026-10-09 15:54","pubTimestamp":1791532440,"startTime":"0","endTime":"0","summary":"但凯莱英的成长轨迹，或比药明系标的更受全球创新药资本周期牵制。凯莱英的订单对Biotech融资环境敏感度要高于平台型CXO，一旦海外融资再度收紧，新增订单会快速承压；2）小分子赛道产能过剩。在港股CXO的资产池中，凯莱英属于高弹性、高周期属性的细分标的，收益与波动并存。立足港股生物医药产业专业化分工与长期成长逻辑，持续甄别CXO细分赛道龙头的壁垒优势与周期潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514419&idx=1&sn=03bcad549927d1049f882ae64191e5f9&chksm=f341fc127046e086c335c9021737db79bb04354bdf38d693ebc6189ccc53974114487a15b9f5&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1191","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118533974","title":"异动解读｜凯莱英盘中下跌3.37%，机构密集减持叠加节后避险情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1118533974","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118533974?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:33","pubTimestamp":1791509628,"startTime":"0","endTime":"0","summary":"10月9日，凯莱英盘中下跌3.37%，报157.3港元，成交额295.21万港元。消息面上，近期多家机构连续减持凯莱英H股，对市场情绪形成压制。机构密集调仓叠加节后避险情绪，导致股价承压。公司基本面仍有亮点，在手订单16.73亿美元同比增长53.77%，化学大分子基地通过美国FDA批准前检查，但短期外资减持压力占据主导。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"凯莱英盘中下跌，机构密集减持施压","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674892318","title":"【券商聚焦】中泰国际：多家药企将公布重要数据 推荐创新药与CXO龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2674892318","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674892318?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:38","pubTimestamp":1791506310,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际表示，多家创新药企业将于10月下旬ESMO公布重要临床数据。ESMO是欧洲最具盛名和影响力的肿瘤学会议，LBA是最高级别的研究成果展示，因此ESMO公布的LBA在医药行业广受关注。中国企业入选的LBA中，有四项入选最高级别的主席研讨会。该机构认为，以上情况表明中国创新药研发能力在海外广受认可，因此创新药板块值得继续关注。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993342","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","LU0067412154.USD","02359","00013","LU0708995153.HKD","LU0348827113.USD","LU0029874905.USD","IE0008369823.USD","159992","LU2097828557.USD","LU0823426308.USD","LU2399975544.HKD","IBBQ","LU1242518931.SGD","LU1008478684.HKD","LU0320764599.SGD","LU1688375341.USD","LU0149534421.HKD","LU2097828714.EUR","01801","06821","MEDX","LU0561508036.HKD","LU1831875114.USD","BK1500","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP","LU0314109678.HKD","WX","01093","09926","KCE","06978","01177","LU0307460666.USD","CXO","LU1960683339.HKD","SG9999002463.SGD","LU2125910500.SGD","BK1521","LU0348783233.USD","LU2488822045.USD","LU0572944931.SGD","BK1191","LU0348767384.USD","02268","06160","02269","KURE","LU0327786744.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2673073813","title":"凯莱英（002821）披露证券变动月报表，10月8日股价下跌4.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673073813","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673073813?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:41","pubTimestamp":1791452503,"startTime":"0","endTime":"0","summary":"截至2026年10月8日收盘，凯莱英报收于180.68元，较前一交易日下跌4.21%，最新总市值为653.97亿元。该股当日开盘188.1元，最高188.22元，最低180.18元，成交额达13.99亿元，换手率为2.4%。凯莱英于近日披露《证券变动月报表》。公告显示，截至2026年9月30日，公司A股类别普通股注册股份数目增加1,285,200股，注册资本相应增加1,285,200元人民币；H股类别股份无变动。本月因股权激励计划实际新增发行A股1,285,200股，库存股A股减少1,151,300股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800023180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","161027","LU1328615791.USD","BK0132","BK0239","002821","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186900702","title":"异动解读｜凯莱英盘中下跌3.02%，机构减持与节前避险情绪压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1186900702","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186900702?lang=zh_cn&edition=full","pubTime":"2026-10-08 14:37","pubTimestamp":1791441451,"startTime":"0","endTime":"0","summary":"10月8日，凯莱英盘中下跌3.02%，报160.5港元，成交额6960.41万港元。消息面上，近期多家机构对凯莱英H股进行了减持操作。摩根大通于9月23日以每股均价159.1287港元场外卖出8.32万股，好仓比例降至8.8%；施罗德于9月24日减持17.58万股，每股作价约150.23港元。机构连续减持行为对市场情绪形成一定压制。尽管公司基本面仍有亮点，包括在手订单16.73亿美元同比增长53.77%，以及化学大分子基地通过美国FDA批准前检查，但节前避险情绪与外资调仓压力叠加，导致股价承压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"凯莱英盘中下跌，机构节前减持施压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113518628","title":"凯莱英9月股份变动月报：A股注册股本增至334,114,160股","url":"https://stock-news.laohu8.com/highlight/detail?id=1113518628","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113518628?lang=zh_cn&edition=full","pubTime":"2026-10-07 12:06","pubTimestamp":1791346016,"startTime":"0","endTime":"0","summary":"凯莱英医药集团（天津）股份有限公司于2026年10月7日披露截至2026年9月30日的证券变动月报。公告显示，本月A股法定/注册股本由上月底的332,828,960股增加1,285,200股至334,114,160股；H股法定/注册股本维持在27,834,510股不变。本月底公司法定/注册股本总额为人民币361,948,670元。新增股份主要源于2026年8月20日经股东大会通过的2026年A股限制性股票激励计划，共计授出1,285,200股并动用库存股1,151,300股。H股方面本月无新增发行、购回或注销活动，已发行H股仍为27,834,510股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167080606","title":"异动解读｜凯莱英盘中下跌3.87%，机构减持与节前避险情绪压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1167080606","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167080606?lang=zh_cn&edition=full","pubTime":"2026-10-07 09:35","pubTimestamp":1791336936,"startTime":"0","endTime":"0","summary":"10月7日，凯莱英盘中下跌3.87%，报163.2港元，成交额60.88万港元。消息面上，近期多家机构对凯莱英H股进行了减持操作。摩根大通于9月23日以每股均价159.1287港元场外卖出8.32万股，好仓比例降至8.8%；施罗德于9月24日减持17.58万股，每股作价约150.23港元。机构连续减持行为对市场情绪形成一定压制。尽管公司基本面仍有亮点，包括在手订单16.73亿美元同比增长53.77%，以及化学大分子基地通过美国FDA批准前检查，但节前避险情绪与外资调仓压力叠加，导致股价承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"凯莱英盘中下挫，机构减持叠加节前避险","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136408163","title":"异动解读｜凯莱英盘中下跌3.35%，报160.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136408163","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136408163?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:45","pubTimestamp":1790905545,"startTime":"0","endTime":"0","summary":"10月2日，凯莱英盘中下跌3.35%，报160.2港元/股，成交额752.02万港元。凯莱英所在的制药行业中，板块整体走弱，个股中，翰森制药跌4.31%，石药集团跌3.62%，恒瑞医药跌3.94%，中国生物制药跌4.12%，先声药业跌5.06%。凯莱英医药集团（天津）股份有限公司是一家主要从事提供医药外包一站式综合服务的公司，业务包括小分子药物CDMO、化学大分子CDMO、临床研究服务、制剂CDMO及生物大分子CDMO等，产品类别涵盖多肽、寡核苷酸、单克隆抗体、抗体偶联药物和信使RNA等。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671274703","title":"9月30日凯莱英涨5.30%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2671274703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671274703?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:37","pubTimestamp":1790757444,"startTime":"0","endTime":"0","summary":"证券之星消息，9月30日凯莱英涨5.30%，收盘报188.62元，换手率3.34%，成交量10.6万手，成交额19.63亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共153家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为127.36亿元，最新净值1.9547，较上一交易日上涨0.16%，近一年下跌4.01%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000025864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0239","002821","06821","LU1328615791.USD","BK0132","159760"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.asymchem.com","stockEarnings":[{"period":"1week","weight":-0.1128},{"period":"1month","weight":-0.1635},{"period":"3month","weight":0.1741},{"period":"6month","weight":0.417},{"period":"1year","weight":0.4662},{"period":"ytd","weight":0.9593}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"凯莱英医药集团（天津）股份有限公司是一家主要从事提供医药外包一站式综合服务的中国公司。该公司的业务包括小分子药物定制研发生产（CDMO）、化学大分子CDMO、临床研究服务、制剂CDMO、生物大分子CDMO、技术输出和合成生物技术。该公司的产品类别涵盖多肽、寡核苷酸、单克隆抗体、抗体偶联药物和信使RNA等。该公司主要在国内外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.058449},{"month":2,"riseRate":0.4,"avgChangeRate":0.006895},{"month":3,"riseRate":0.4,"avgChangeRate":0.004398},{"month":4,"riseRate":0.6,"avgChangeRate":-0.036171},{"month":5,"riseRate":0.4,"avgChangeRate":0.006805},{"month":6,"riseRate":0.6,"avgChangeRate":0.053806},{"month":7,"riseRate":0.6,"avgChangeRate":0.056483},{"month":8,"riseRate":0.4,"avgChangeRate":-0.032767},{"month":9,"riseRate":0.8,"avgChangeRate":0.210834},{"month":10,"riseRate":0,"avgChangeRate":-0.138939},{"month":11,"riseRate":0.5,"avgChangeRate":0.010601},{"month":12,"riseRate":0.25,"avgChangeRate":-0.010173}],"exchange":"SEHK","name":"凯莱英","nameEN":"ASYMCHEM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯莱英(06821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯莱英,06821,凯莱英股票,凯莱英股票老虎,凯莱英股票老虎国际,凯莱英行情,凯莱英股票行情,凯莱英股价,凯莱英股市,凯莱英股票价格,凯莱英股票交易,凯莱英股票购买,凯莱英股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯莱英(06821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}